New sedative shows promise for Long-Term ICU sedation
NCT ID NCT05913336
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a sedative called remimazolam tosilate in 24 ICU patients who needed to be on a breathing machine for at least three days. The goal was to see if the drug could keep patients at the right sedation level safely. Because this is a small, non-randomized study, the results are preliminary and more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remimazolam tosilate
- What this could lead to
- If successful, this could provide a safer or more controllable sedation option for ICU patients who need to be on a breathing machine for days.
- What could go wrong
- This is a very early, small study (24 people) with no comparison group, so results may not apply broadly. The drug may not work as well as current sedatives or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEDATION IN THE ICU are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.